GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elevation Oncology Inc (NAS:ELEV) » Definitions » 14-Day RSI

Elevation Oncology (Elevation Oncology) 14-Day RSI

: 38.69 (As of Today)
View and export this data going back to 2021. Start your Free Trial

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-04-19), Elevation Oncology's 14-Day RSI is 38.69.

The industry rank for Elevation Oncology's 14-Day RSI or its related term are showing as below:

ELEV's 14-Day RSI is ranked better than
60.25% of 1575 companies
in the Biotechnology industry
Industry Median: 41.55 vs ELEV: 38.69

Competitive Comparison

For the Biotechnology subindustry, Elevation Oncology's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elevation Oncology 14-Day RSI Distribution

For the Biotechnology industry and Healthcare sector, Elevation Oncology's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Elevation Oncology's 14-Day RSI falls into.



Elevation Oncology  (NAS:ELEV) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elevation Oncology  (NAS:ELEV) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Elevation Oncology 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Elevation Oncology's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Elevation Oncology (Elevation Oncology) Business Description

Traded in Other Exchanges
N/A
Address
888 Seventh Avenue, 12th Floor, New York, NY, USA, 10106
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
Executives
Tammy Furlong officer: CHIEF FINANCIAL OFFICER C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Venbio Global Strategic Gp Iii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Fund Iii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Goodman Corey S 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Robert J Adelman 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Aaron Royston 10 percent owner 200 CARDINAL WAY, 2ND FLOOR, REDWOOD CITY CA 94063
David Dornan officer: Chief Scientific Officer C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063
Valerie Malyvanh Jansen officer: Chief Medical Officer C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Andrew N Schiff other: Managing Member PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Steve Elms director, other: Managing Member 888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Venbio Global Strategic Gp Iii, Ltd 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158
Qiming U.s. Healthcare Gp Ii, Llc 10 percent owner 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Vertex Global Hc Fund Ii Pte. Ltd. 10 percent owner 250 NORTH BRIDGE ROAD, #11-01 RAFFLES CITY TOWER, SINGAPORE U0 179101
Walsh Colin director C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106

Elevation Oncology (Elevation Oncology) Headlines

From GuruFocus